Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;25(13):1809-1818.
doi: 10.1177/1352458518809326. Epub 2018 Nov 1.

International consensus on quality standards for brain health-focused care in multiple sclerosis

Jeremy Hobart  1 , Amy Bowen  2 , George Pepper  3 , Harriet Crofts  4 , Lucy Eberhard  4 , Thomas Berger  5 , Alexey Boyko  6 , Cavit Boz  7 , Helmut Butzkueven  8 , Elisabeth Gulowsen Celius  9 , Jelena Drulovic  10 , José Flores  11 , Dana Horáková  12 , Christine Lebrun-Frénay  13 , Ruth Ann Marrie  14 , James Overell  15 , Fredrik Piehl  16 , Peter Vestergaard Rasmussen  17 , Maria José Sá  18 , Carmen-Adella Sîrbu  19 , Eli Skromne  20 , Øivind Torkildsen  21 , Vincent van Pesch  22 , Timothy Vollmer  23 , Magd Zakaria  24 , Tjalf Ziemssen  25 , Gavin Giovannoni  26
Affiliations

International consensus on quality standards for brain health-focused care in multiple sclerosis

Jeremy Hobart et al. Mult Scler. 2019 Nov.

Abstract

Background: Time matters in multiple sclerosis (MS). Irreversible neural damage and cell loss occur from disease onset. The MS community has endorsed a management strategy of prompt diagnosis, timely intervention and regular proactive monitoring of treatment effectiveness and disease activity to improve outcomes in people with MS.

Objectives: We sought to develop internationally applicable quality standards for timely, brain health-focused MS care.

Methods: A panel of MS specialist neurologists participated in an iterative, online, modified Delphi process to define 'core', 'achievable' and 'aspirational' time frames reflecting minimum, good and high care standards, respectively. A multidisciplinary Reviewing Group (MS nurses, people with MS, allied healthcare professionals) provided insights ensuring recommendations reflected perspectives from multiple stakeholders.

Results: Twenty-one MS neurologists from 19 countries reached consensus on most core (25/27), achievable (25/27) and aspirational (22/27) time frames at the end of five rounds. Agreed standards cover six aspects of the care pathway: symptom onset, referral and diagnosis, treatment decisions, lifestyle, disease monitoring and managing new symptoms.

Conclusion: These quality standards for core, achievable and aspirational care provide MS teams with a three-level framework for service evaluation, benchmarking and improvement. They have the potential to produce a profound change in the care of people with MS.

Keywords: Delphi technique; Multiple sclerosis; benchmarking; consensus; quality improvement; standards.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.H. has received consulting fees, honoraria, support to attend meetings or research support from Acorda, Asubio, Bayer Schering, Biogen Idec, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis and Teva. G.P. has received consulting fees from Biogen, Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis and Teva. H.C. and L.E. are employees of Oxford PharmaGenesis Ltd., and work on this study was carried out as part of their role at the company. A.Boyko. has received honoraria as a member of working groups and advisory boards and participated in clinical trials for Biogen, Schering, Merck, Teva, Novartis, Sanofi Genzyme, Actelion, Biocad and Generium. H.B. has received personal fees from Biogen, Merck, Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis and Teva, and research support from Biogen and Novartis. E.G.C. has received personal fees from Almirall, Biogen, Merck, Roche and Teva, and grants and personal fees from Novartis and Sanofi. J.D. has received fees for serving on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva, Genzyme, a Sanofi Company, Roche; has received speaker honoraria from Merck Serono, Teva, Bayer Schering, Genzyme, a Sanofi Company, Medis and Roche; and has received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031). D.H. has received grants from Czech Ministry of Education project Progres Q27/LF1, and speaker honoraria, travel expenses and consultancy fees from Biogen, Novartis, Merck, Roche, Sanofi Genzyme and Teva. J.O. has received grants, personal fees and non-financial support from Biogen, Novartis, Roche and Genzyme, and personal fees and non-financial support from Allergan, Merck and Teva. F.P. has received research grants from Biogen, Novartis and Genzyme, and fees for serving as Chair of DMC in clinical trials with Parexel. P.V.R. has received grant support from Novartis; has received fees for acting as a consultant or advisory board member for Allergan, Biogen, Merck, Novartis, Roche, Sanofi-Aventis and Teva; and has received speaker fees from Teva. M.J.S. has received speaker and/or consulting fees from Bayer, Biogen, CSL Behring, Merck, Novartis, Roche, Sanofi Genzyme and Teva. C.-A.S. has received conference expenses from Bayer, Medison Pharma, Merck, Novartis and Teva. Ø.T. has received speaker honoraria and fees for serving on scientific advisory boards from Biogen, Merck and Sanofi-Aventis, and has received speaker honoraria from Novartis. V.v.P. has received travel grants from Biogen, Genzyme, Merck, Teva, Roche and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Sanofi, Novartis Pharma and Roche. T.V. has received compensation for acting as a consultant, speaker or advisory board member for Academic CME, Alcimed, Anthem Blue Cross, Genentech/Roche, Biogen IDEC, Novartis, CellGene, Epigene, Rocky Mountain MS Center, GLG Consulting, Ohio Health, Oxford Health Policy Forum, Oxford PharmaGenesis, TG Therapeutics, Topaz Therapeutics, Dleara Lawyers and Teva Neuroscience, and has received research support from Teva Neuroscience, NIH/NINDS, Rocky Mountain MS Center, Actelion, Biogen, Novartis, Roche/Genentech and TG Therapeutics, Inc. T.Z. has received grants and personal fees from Biogen, Novartis, Sanofi and Teva, and personal fees from Almirall, Bayer, Merck, Oxford Health Policy Forum and Roche. G.G. has received consulting fees from AbbVie, Atara Biotherapeutics, Almirall, Biogen, Celgene, GlaxoSmithKline, MedDay Pharmaceuticals, Merck and Company (USA), Merck Group (Europe), Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis, Roche, Sanofi Genzyme, Synthon, Takeda, Teva Pharmaceutical Industries Ltd. and UCB, and has received research support from Biogen, Sanofi Genzyme and Takeda. A.Bowen., C.B., T.B., J.F., C.L.-F., R.A.M., E.S. and M.Z. declare no competing interests.

Figures

Figure 1.
Figure 1.
Study flow for the MS Brain Health Delphi process. MS: multiple sclerosis.
Figure 2.
Figure 2.
Consensus standards for timely, brain health-focused MS care agreed by at least 75% of the Delphi Consensus Panel related to (a) referral and diagnosis, (b) priorities following diagnosis, (c) routine monitoring and support, (d) treatment decisions, (e) new symptoms and (f) additional statements that were not time limited. DMT: disease-modifying therapy; MRI: magnetic resonance imaging; MS: multiple sclerosis. *Time frame of 3 months was agreed by the Delphi Panel after completion of the Delphi process.
Figure 3.
Figure 3.
Achievable consensus standards for the timing of key events in a brain health-focused MS care pathway related to (a) referral and diagnosis, (b) priorities following diagnosis, (c) routine monitoring and support, (d) treatment decisions and (e) new symptoms. DMT: disease-modifying therapy; MRI: magnetic resonance imaging; MS: multiple sclerosis.
See this image and copyright information in PMC

Comment in

References

    1. Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 1368–1374. - PubMed
    1. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: What you’ve got and how you use it. Neurology 2013; 80: 2186–2193. - PMC - PubMed
    1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9(Suppl. 1): S5–S48. - PubMed
    1. Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology 2015; 84: 1582–1591. - PMC - PubMed
    1. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944–953. - PubMed

Publication types